All zymeworks articles

  • Concept,Image,Of,An,Anticancer,Drug,Called,Adc.,3d,Rendering
    Article

    Unlocking the potential of antibody drug conjugates

    2024-05-01T10:00:29Z

    Zymeworks’ Dr Paul Moore, Dr Raffaele Colombo and Dr Jamie Rich discuss how advancements in ADCs are redefining cancer treatment. They elucidate the innovative strategies that are being developed to improve drug stability and how personalised medicine approaches are optimising outcomes for individual cancer patients, offering new hope across several ...

  • Paul Moore
    Article

    Breakthrough drug candidates and cancer treatment innovations

    2023-06-05T16:00:22Z

    In this exclusive interview with Dr Paul Moore, Chief Scientific Officer from Zymeworks, we explore the impressive responses of Zymeworks' antibody-drug conjugate ZW191 in FRα-low expressing models, indicating its efficacy in treating various oncology indications.